These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 24083670)

  • 21. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials.
    Petrou P; Gothelf Y; Argov Z; Gotkine M; Levy YS; Kassis I; Vaknin-Dembinsky A; Ben-Hur T; Offen D; Abramsky O; Melamed E; Karussis D
    JAMA Neurol; 2016 Mar; 73(3):337-44. PubMed ID: 26751635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Final Results of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells in Acute Ischemic Stroke (AMASCIS): A Phase II, Randomized, Double-Blind, Placebo-Controlled, Single-Center, Pilot Clinical Trial.
    de Celis-Ruiz E; Fuentes B; Alonso de Leciñana M; Gutiérrez-Fernández M; Borobia AM; Gutiérrez-Zúñiga R; Ruiz-Ares G; Otero-Ortega L; Laso-García F; Gómez-de Frutos MC; Díez-Tejedor E
    Cell Transplant; 2022; 31():9636897221083863. PubMed ID: 35301883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stem cell transplantation for ischemic stroke.
    Boncoraglio GB; Bersano A; Candelise L; Reynolds BA; Parati EA
    Cochrane Database Syst Rev; 2010 Sep; (9):CD007231. PubMed ID: 20824857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Research on advanced intervention using novel bone marrOW stem cell (RAINBOW): a study protocol for a phase I, open-label, uncontrolled, dose-response trial of autologous bone marrow stromal cell transplantation in patients with acute ischemic stroke.
    Shichinohe H; Kawabori M; Iijima H; Teramoto T; Abumiya T; Nakayama N; Kazumata K; Terasaka S; Arato T; Houkin K
    BMC Neurol; 2017 Sep; 17(1):179. PubMed ID: 28886699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized clinical trial: expanded autologous bone marrow mesenchymal cells combined with allogeneic bone tissue, compared with autologous iliac crest graft in lumbar fusion surgery.
    García de Frutos A; González-Tartière P; Coll Bonet R; Ubierna Garcés MT; Del Arco Churruca A; Rivas García A; Matamalas Adrover A; Saló Bru G; Velazquez JJ; Vila-Canet G; García-Lopez J; Vives J; Codinach M; Rodriguez L; Bagó Granell J; Càceres Palou E
    Spine J; 2020 Dec; 20(12):1899-1910. PubMed ID: 32730985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis.
    Petrou P; Kassis I; Levin N; Paul F; Backner Y; Benoliel T; Oertel FC; Scheel M; Hallimi M; Yaghmour N; Hur TB; Ginzberg A; Levy Y; Abramsky O; Karussis D
    Brain; 2020 Dec; 143(12):3574-3588. PubMed ID: 33253391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic adipose tissue-derived mesenchymal stem cells in ischaemic stroke (AMASCIS-02): a phase IIb, multicentre, double-blind, placebo-controlled clinical trial protocol.
    de Celis-Ruiz E; Fuentes B; Moniche F; Montaner J; Borobia AM; Gutiérrez-Fernández M; Díez-Tejedor E
    BMJ Open; 2021 Aug; 11(8):e051790. PubMed ID: 34373315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversal of the neurological deficit in acute stroke with the signal of efficacy trial of auto-BPAP to limit damage from suspected sleep apnea (Reverse-STEAL): study protocol for a randomized controlled trial.
    Kepplinger J; Barlinn K; Kolieskova S; Shahripour RB; Pallesen LP; Schrempf W; Graehlert X; Schwanebeck U; Sisson A; Zerna C; Puetz V; Reichmann H; Albright KC; Alexandrov AW; Vosko M; Mikulik R; Bodechtel U; Alexandrov AV
    Trials; 2013 Aug; 14():252. PubMed ID: 23941576
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale and design of a randomized controlled trial of allogeneic mesenchymal stem cells in patients with nonischemic cardiomyopathy.
    Greene SJ; Epstein SE; Kim RJ; Quyyumi AA; Cole RT; Anderson AS; Wilcox JE; Skopicki HA; Sikora S; Verkh L; Tankovich NI; Gheorghiade M; Butler J
    J Cardiovasc Med (Hagerstown); 2017 Apr; 18(4):283-290. PubMed ID: 26479144
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Phase 2 Randomized, Sham-Controlled Trial of Internal Carotid Artery Infusion of Autologous Bone Marrow-Derived ALD-401 Cells in Patients With Recent Stable Ischemic Stroke (RECOVER-Stroke).
    Savitz SI; Yavagal D; Rappard G; Likosky W; Rutledge N; Graffagnino C; Alderazi Y; Elder JA; Chen PR; Budzik RF; Tarrel R; Huang DY; Hinson JM
    Circulation; 2019 Jan; 139(2):192-205. PubMed ID: 30586746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autologous mesenchymal stromal cells embedded in tricalcium phosphate for posterolateral spinal fusion: results of a prospective phase I/II clinical trial with long-term follow-up.
    Blanco JF; Villarón EM; Pescador D; da Casa C; Gómez V; Redondo AM; López-Villar O; López-Parra M; Muntión S; Sánchez-Guijo F
    Stem Cell Res Ther; 2019 Feb; 10(1):63. PubMed ID: 30795797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and Effectiveness of Intravascular Mesenchymal Stem Cells to Treat Organ Failure and Possible Application in COVID-19 Complications.
    Atluri S; Manocha V; Boddu N; Bhati S; Syed Z; Diwan S; Manchikanti L
    Pain Physician; 2020 Aug; 23(4S):S391-S420. PubMed ID: 32942796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial.
    Butler J; Epstein SE; Greene SJ; Quyyumi AA; Sikora S; Kim RJ; Anderson AS; Wilcox JE; Tankovich NI; Lipinski MJ; Ko YA; Margulies KB; Cole RT; Skopicki HA; Gheorghiade M
    Circ Res; 2017 Jan; 120(2):332-340. PubMed ID: 27856497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two-year clinical follow-up of the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in The Netherlands (MR CLEAN): design and statistical analysis plan of the extended follow-up study.
    van den Berg LA; Dijkgraaf MG; Berkhemer OA; Fransen PS; Beumer D; Lingsma H; Majoie CB; Dippel DW; van der Lugt AJ; van Oostenbrugge RJ; van Zwam WH; Roos YB;
    Trials; 2016 Nov; 17(1):555. PubMed ID: 27876083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments.
    Connick P; Kolappan M; Patani R; Scott MA; Crawley C; He XL; Richardson K; Barber K; Webber DJ; Wheeler-Kingshott CA; Tozer DJ; Samson RS; Thomas DL; Du MQ; Luan SL; Michell AW; Altmann DR; Thompson AJ; Miller DH; Compston A; Chandran S
    Trials; 2011 Mar; 12():62. PubMed ID: 21366911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of DW-MSC infusion in patients with low clinical risk COVID-19 infection: a randomized, double-blind, placebo-controlled trial.
    Karyana M; Djaharuddin I; Rif'ati L; Arif M; Choi MK; Angginy N; Yoon A; Han J; Josh F; Arlinda D; Narulita A; Muchtar F; Bakri RA; Irmansyah S
    Stem Cell Res Ther; 2022 Apr; 13(1):134. PubMed ID: 35365239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancing the Therapeutic Potential of
    Lee S; Kim OJ; Lee KO; Jung H; Oh SH; Kim NK
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit
    Bolli R; Hare JM; March KL; Pepine CJ; Willerson JT; Perin EC; Yang PC; Henry TD; Traverse JH; Mitrani RD; Khan A; Hernandez-Schulman I; Taylor DA; DiFede DL; Lima JAC; Chugh A; Loughran J; Vojvodic RW; Sayre SL; Bettencourt J; Cohen M; Moyé L; Ebert RF; Simari RD;
    Circ Res; 2018 Jun; 122(12):1703-1715. PubMed ID: 29703749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. iTRAQ-based proteomic analysis after mesenchymal stem cell line transplantation for ischemic stroke.
    Mitaki S; Nagai A; Wada Y; Onoda K; Md Sheikh A; Adachi E; Matsumoto KI; Yamaguchi S
    Brain Res; 2020 Sep; 1742():146900. PubMed ID: 32445714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema.
    Stolk J; Broekman W; Mauad T; Zwaginga JJ; Roelofs H; Fibbe WE; Oostendorp J; Bajema I; Versteegh MI; Taube C; Hiemstra PS
    QJM; 2016 May; 109(5):331-6. PubMed ID: 26819296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.